Zevra Therapeutics, Inc. ZVRA Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s stock-based comp?
- Zevra Therapeutics, Inc. (ZVRA) reported stock-based comp of $3.11M in Q1 2026.
- How has Zevra Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Zevra Therapeutics, Inc.'s stock-based comp decreased by 0.3% year-over-year, from $3.12M to $3.11M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Zevra Therapeutics, Inc.'s stock-based comp has grown at a 50.9% compound annual growth rate (CAGR), from $2.44M to $12.63M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.